Far out that would be unsettling as a shareholder.
Just wondering how thorough Pfizer's due diligence was in deciding to underwrite the trial.
Same thing could very easily happen to Mesoblast if a clinical trial were to fail.
Does anyone know if there is a significant difference in the quality of stem cell technology between Athersys & Mesoblast? Does Athersys use Mesenchymal stem cells or a different class/family of stem cells?
M79
- Forums
- ASX - By Stock
- fda study unprecedented !
Far out that would be unsettling as a shareholder.Just wondering...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.01 |
Change
-0.060(5.63%) |
Mkt cap ! $1.141B |
Open | High | Low | Value | Volume |
$1.04 | $1.04 | 99.5¢ | $3.029M | 2.992M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 85516 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 41476 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 85516 | 1.000 |
33 | 243802 | 0.995 |
16 | 199277 | 0.990 |
6 | 107113 | 0.985 |
12 | 61262 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
1.005 | 41476 | 10 |
1.010 | 39002 | 10 |
1.015 | 40373 | 8 |
1.020 | 104131 | 8 |
1.025 | 65418 | 6 |
Last trade - 15.08pm 04/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |